Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Listerine Professional Gum Therapy** is a locally applied oral-rinse product for treatment and prevention of gingivitis. Current official Norwegian labeling identifies ethyl lauroyl arginate hydrochloride as the active antimicrobial ingredient at 0.14% w/w and classifies the product as a medical device; the product is intended to form a protective barrier on the acquired enamel pellicle that reduces bacterial adhesion and dental-biofilm formation. ([listerine.no](https://www.listerine.no/produkter/listerine-professional-gum-therapy)) A randomized 21-day experimental-gingivitis study of the branded product formulation described at the time as containing ethyl lauroyl arginate plus essential oils reported lower plaque scores than controls without mechanical cleaning, but concluded that residual plaque was sufficient to cause gingivitis and questioned the clinical benefit of the rinse alone. ([actaorthop.org](https://actaorthop.org/actaodontologica/article/download/35498/40594))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Listerine Professional Gum Therapy.